Foundation Sponsors

Ferring Ventures Group

Ferring Ventures Group manages a portfolio of research-driven companies around the globe that are committed to the development of life-changing treatments for life-shortening diseases. Headquartered in Switzerland, Ferring Ventures is privately-owned, founded in 2014. Alongside its sister company, Ferring Pharmaceuticals, it forms an integral part of the Ferring Foundation. Ferring Ventures invests heavily in its research infrastructure both in terms of people and technology to enable the discovery of innovative medicines including novel gene and cell therapies, that have the potential to transform the lives of patients. The Ferring Ventures organization is spread across key locations in Europe (St-Prex Switzerland, Hamburg Germany, London UK, Kuopio Finland) and in the US (San Diego). Ferring Ventures San Diego is advancing a pipeline of peptide-based radiopharmaceuticals that builds on the foundations of Ferring Pharmaceuticals, a world leading pharmaceutical company with one of the largest peptide therapeutic portfolios.

PolyPeptide

PolyPeptide is a publicly listed organization, traded on the Swiss stock exchange, which focuses on manufacturing proprietary and generic GMP-grade peptides and oligonucleotides for the pharmaceutical and biotechnological market. With more than 60 years of experience, PolyPeptide is committed to the highest quality of manufacturing for commercial peptide drug substances, GMP peptides in clinical trials, or small-scale pre-clinical custom syntheses.

As an organization, PolyPeptide has grown by selective acquisition of existing expertise, culminating in its position today as a leader in peptide manufacturing. With three manufacturing facilities in Europe, two facilities in the US , and one in Asia, PolyPeptide is a multinational company with about 1200 employees worldwide with a diversity which brings breadth and depth of knowledge, as well as unique experience to the organization.

PolyPeptide’s long-established core strength is in GMP manufacturing, and a broad range of services which supports peptide & peptide-like projects, including conjugation to non-peptide moieties, from bench scale through to commercialization. With continually increasing capacity for GMP manufacturing, PolyPeptide is uniquely placed to serve the needs of its customers at all stages of pharmaceutical peptide development with a proven track record in security of supply to its clients.

Zealand Pharma

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) (“Zealand”) is a biotechnology company specialized in the discovery, design and development of peptide-based therapeutics. The company has a portfolio of medicines and product candidates under license collaborations with Sanofi and Boehringer Ingelheim and a proprietary pipeline of product candidates, which primarily target specialty diseases with significant unmet needs.
Zealand is the inventor of lixisenatide, a once-daily prandial GLP-1 analog for the treatment of type 2 diabetes, which is licensed to Sanofi and marketed globally outside the U.S. as Lyxumia® and in the U.S. as Adlyxin®. Sanofi has also developed iGlarLixi, a fixed-ratio combination of lixisenatide and Lantus® (insulin glargine) marketed in U.S. as Soliqua® and Europe as Suliqua®.
Zealand’s proprietary pipeline includes; glepaglutide*, a GLP-2 analog for the treatment of short bowel syndrome which will initiate Phase III studies in 1H18; dasiglucagon*, a glucagon analog in Phase III as a single-dose rescue therapy for severe hypoglycemia and in Phase II as a multiple-dose component in a dual-hormone artificial pancreas system; and other earlier stage clinical and preclinical peptide therapeutics. The company has approximately 130 employees and is based in Copenhagen, Denmark.
* Glepaglutide and dasiglucagon are proposed International Nonproprietary Names (pINNs)